BEXIMCO PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.5 GBX | 0.00% |
|
-1.35% | -12.05% |
| Mar. 04 | Beximco names Iqbal Ahmed as managing director | AN |
| Jan. 30 | Beximco Pharmaceuticals to strengthen portfolio as interim profit up | AN |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Its low valuation, with P/E ratio at 9.44 and 7.69 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -12.05% | 472M | - | ||
| +25.83% | 661B | C+ | ||
| +27.00% | 566B | B | ||
| -6.76% | 352B | C+ | ||
| +20.34% | 332B | B- | ||
| +3.00% | 283B | C+ | ||
| +13.09% | 231B | B+ | ||
| +5.46% | 200B | B- | ||
| -9.61% | 195B | A+ | ||
| -6.26% | 145B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
- Stock Market
- Equities
- BXPHARMA Stock
- BXP Stock
- Ratings Beximco Pharmaceuticals Limited
